Jonathan Alpert

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:441-7. 2005
  2. ncbi Getting our own house in order: improving psychiatry education to medical students as a prelude to medical school education reform
    Jonathan E Alpert
    Harvard Medical School, Boston, MA 02114, USA
    Acad Psychiatry 30:170-3. 2006
  3. ncbi S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine
    Jonathan E Alpert
    Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:661-4. 2004
  4. ncbi Enrolling research subjects from clinical practice: ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial
    Jonathan E Alpert
    Massachusetts General Hospital, Depression Clinical and Research Program, 50 Staniford Street, 4th Floor, Boston, 02114, USA
    Psychiatry Res 141:193-200. 2006
  5. ncbi Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression
    Jonathan E Alpert
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
    Ann Clin Psychiatry 14:33-8. 2002
  6. ncbi Major depressive disorder with anger attacks and cardiovascular risk factors
    Renerio Fraguas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, USA
    Int J Psychiatry Med 37:99-111. 2007
  7. ncbi Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD
    Amy Farabaugh
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Depress Anxiety 24:433-9. 2007
  8. ncbi Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study
    Renerio Fraguas
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston, MA 02114, USA
    Psychosomatics 48:418-25. 2007
  9. ncbi Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression
    Roy H Perlis
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Psychosomatics 45:224-9. 2004
  10. ncbi Relationships between major depressive disorder and comorbid anxiety and personality disorders
    Amy Farabaugh
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Compr Psychiatry 46:266-71. 2005

Research Grants

  1. RESPONSE VARIABILITY IN TREATMENT RESISTANT DEPRESSION
    Jonathan Alpert; Fiscal Year: 2006

Detail Information

Publications83

  1. ncbi A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:441-7. 2005
    ..This study looks to compare the antidepressant efficacy and safety of a standardized extract of St John's wort with both placebo and fluoxetine...
  2. ncbi Getting our own house in order: improving psychiatry education to medical students as a prelude to medical school education reform
    Jonathan E Alpert
    Harvard Medical School, Boston, MA 02114, USA
    Acad Psychiatry 30:170-3. 2006
    ..The authors summarize efforts to revitalize psychiatry teaching to medical students at Harvard Medical School (HMS) in advance of a major overhaul of the medical school curriculum...
  3. ncbi S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine
    Jonathan E Alpert
    Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:661-4. 2004
    ..The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine...
  4. ncbi Enrolling research subjects from clinical practice: ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial
    Jonathan E Alpert
    Massachusetts General Hospital, Depression Clinical and Research Program, 50 Staniford Street, 4th Floor, Boston, 02114, USA
    Psychiatry Res 141:193-200. 2006
    ....
  5. ncbi Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression
    Jonathan E Alpert
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
    Ann Clin Psychiatry 14:33-8. 2002
    ..Leucovorin appears to be modestly effective as an adjunct among SSRI-refractory depressed individuals with normal folate levels. The application of leucovorin as an adjunct in the setting of refractory depression deserves further study...
  6. ncbi Major depressive disorder with anger attacks and cardiovascular risk factors
    Renerio Fraguas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, USA
    Int J Psychiatry Med 37:99-111. 2007
    ..Depression and anger have been separately associated with cardiovascular risk factors. We investigated if major depressive disorder (MDD) with concomitant anger attacks was associated with cardiovascular risk factors...
  7. ncbi Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD
    Amy Farabaugh
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Depress Anxiety 24:433-9. 2007
    ..This finding suggests that dysfunctional attitudes that persist beyond remission of MDD may be a marker for certain personality disorders that are stable across long-term treatment...
  8. ncbi Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study
    Renerio Fraguas
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston, MA 02114, USA
    Psychosomatics 48:418-25. 2007
    ..Prospective studies are warranted to confirm these results...
  9. ncbi Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression
    Roy H Perlis
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Psychosomatics 45:224-9. 2004
    ..Medical comorbidity thus does not appear to be associated with significantly poorer outcome among patients whose major depressive disorder failed initially to respond to an initial trial of 20 mg/day of fluoxetine...
  10. ncbi Relationships between major depressive disorder and comorbid anxiety and personality disorders
    Amy Farabaugh
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Compr Psychiatry 46:266-71. 2005
    ....
  11. ncbi Cognitive therapy for anxious depression in STAR(⁎)D: What have we learned?
    Amy Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, United States Electronic address
    J Affect Disord 142:213-8. 2012
    ..The primary aim of this study was to assess the effectiveness of cognitive therapy (CT) alone or in combination with medications for anxious versus non-anxious depression...
  12. ncbi Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
    Control Clin Trials 25:119-42. 2004
    ..Participants with an adequate symptomatic response may enter the 12-month naturalistic follow-up phase with brief monthly and more complete quarterly assessments...
  13. ncbi Anger attacks in major depressive disorder and serum levels of homocysteine
    Renerio Fraguas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 60:270-4. 2006
    ..Increased levels of homocysteine have been associated with anger and depression separately. We investigated the association of anger attacks in major depressive disorder (MDD) with serum levels of homocysteine...
  14. ncbi Melancholia and axis II comorbidity
    Joyce Tedlow
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Compr Psychiatry 43:331-5. 2002
    ....
  15. ncbi Factors that differentiate early vs. later onset of major depression disorder
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, 9500 Gilman Dr, 0603R, La Jolla, CA 92093, USA
    Psychiatry Res 129:127-40. 2004
    ..Thus, pre-adulthood onset MDD is a particularly severe and chronic condition...
  16. ncbi The overlap between personality disorders and major depressive disorder (MDD)
    Amy Farabaugh
    The Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 16:217-24. 2004
    ..Research studies have focused attention on the importance of the comorbidity of personality disorders and depression...
  17. ncbi Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D
    Ira Lesser
    Department of Psychiatry, Harbor UCLA Medical Center, Torrance, CA 90509, USA
    Psychiatr Serv 59:1273-84. 2008
    ....
  18. ncbi Assessing anxious features in depressed outpatients
    Shawn M McClintock
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 8898, USA
    Int J Methods Psychiatr Res 20:e69-82. 2011
    ..Both the HRSD(ANX) and IDS-C(ANX) subscales have acceptable psychometric properties and can be used to identify anxious features for clinical or research purposes...
  19. ncbi Personality disorders and the trimensional personality questionnaire factors in major depressive disorder
    Amy Farabaugh
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Nerv Ment Dis 193:747-50. 2005
    ..Certain temperament traits, especially HA and NS, appear to be associated with specific patterns of personality clusters among depressed patients...
  20. ncbi Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome
    Amy H Farabaugh
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Int Clin Psychopharmacol 25:214-7. 2010
    ..Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome...
  21. ncbi Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Psychopharmacol 22:379-87. 2002
    ....
  22. ncbi Teaching ethics of psychopharmacology research in psychiatric residency training programs
    Eugene V Beresin
    Department of Psychiatry, Massachusetts General Hospital, Bullfinch 449, MA 02114, Boston, USA
    Psychopharmacology (Berl) 171:105-11. 2003
    ..Residents need to understand principles of research ethics and implications of roles of psychiatrists as investigators and clinicians...
  23. ncbi Predictors of stable personality disorder diagnoses in outpatients with remitted depression
    Amy Farabaugh
    Depression and Clinical Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    J Nerv Ment Dis 190:248-56. 2002
    ....
  24. ncbi Antidepressant effects on emotional temperament: toward a biobehavioral research paradigm for major depressive disorder
    David P Soskin
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    CNS Neurosci Ther 18:441-51. 2012
    ..Given the limited efficacy of current pharmacotherapy for major depressive disorder (MDD) and the historical decline in antidepressant development, there is increasing clinical urgency to develop more effective treatments...
  25. ncbi Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3)
    John J Mooney
    Department of Psychiatry, Harvard Medical School, Boston, MA, USA
    J Psychiatr Res 42:605-11. 2008
    ..Inhibition of the extraneuronal monoamine transporter may be an important component in the clinical pharmacology of the norepinephrine reuptake inhibitor antidepressant drugs, such as desipramine...
  26. ncbi Predictors of relapse in a prospective study of fluoxetine treatment of major depression
    Patrick J McGrath
    Depression Evaluation Service, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032 1007, USA
    Am J Psychiatry 163:1542-8. 2006
    ..This study was designed to test the predictive value of response pattern prospectively and to examine the data for other predictors of relapse...
  27. ncbi Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 165:342-51. 2008
    ..The authors conducted a secondary data analysis to compare antidepressant treatment outcomes for patients with anxious and nonanxious major depression in Levels 1 and 2 of the STAR*D study...
  28. ncbi Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study
    Daniel J Pilowsky
    New York State Psychiatric Institute, Columbia University, Unit 24, 1051 Riverside Dr, New York, NY 10032, USA
    Am J Psychiatry 165:1136-47. 2008
    ..The authors examined the changes in psychiatric symptoms and global functioning in children of depressed women 1 year following the initiation of treatment for maternal major depressive disorder...
  29. ncbi Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report
    William S Gilmer
    Asher Center for the Study and Treatment of Depressive Disorders, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    J Clin Psychiatry 69:1246-56. 2008
    ....
  30. ncbi Children of currently depressed mothers: a STAR*D ancillary study
    Daniel J Pilowsky
    Columbia University and the New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    J Clin Psychiatry 67:126-36. 2006
    ....
  31. ncbi What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension
    Maurizio Fava
    Massachusetts General Hospital, Boston, Harvard Medical School, MA 02114, USA
    Can J Psychiatry 51:823-35. 2006
    ..This study was designed to replicate and extend our initial findings in a subsequent, larger cohort of outpatient STAR*D participants with nonpsychotic major depressive disorder (MDD)...
  32. ncbi Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder
    Jonathan E Alpert
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 65:1069-75. 2004
    ..To evaluate the efficacy and tolerability of gepirone extended-release (ER) tablets in patients with major depressive disorder (MDD) and high ratings of anxiety (anxious depression)...
  33. ncbi Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I)
    Dan V Iosifescu
    Massachusetts General Hospital, Department of Psychiatry, Depression Clinical and Research Program, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Psychiatry Res 140:291-9. 2005
    ..In light of the adverse impact of WMHs on a number of health-related outcomes later in life, hypofolatemia and hypertension may represent modifiable risk factors to prevent the occurrence of such adverse outcomes...
  34. ncbi Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II)
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 140:301-7. 2005
    ....
  35. ncbi Outcomes of recognizing depressed Chinese American patients in primary care
    Albert Yeung
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, Massachusetts 02114, USA
    Int J Psychiatry Med 35:213-24. 2005
    ..This study aims to examine the effect of identifying Chinese American patients as having major depressive disorder (MDD) to their primary care physicians (PCPs) on the latter's attention given to the treatment of depression...
  36. ncbi Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort
    Lori L Davis
    Department of Veterans Affairs VA Medical Center, Tuscaloosa, Ala 35404, USA
    J Clin Psychiatry 68:1931-8. 2007
    ....
  37. ncbi Ethnicity/race and outcome in the treatment of depression: results from STAR*D
    Ira M Lesser
    Department of Psychiatry, Harbor UCLA Medical Center, Los Angeles Biomedical Research Institute at Harbor UCLA, 1000 W Carson Street, Torrance, CA 90509, USA
    Med Care 45:1043-51. 2007
    ....
  38. ncbi Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 149:195-200. 2007
    ..Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted...
  39. ncbi A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 67:1754-9. 2006
    ..The purpose of the present work is to examine cross-sectionally the prevalence of cognitive and physical side effects of antidepressants during long-term treatment of depression...
  40. ncbi Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School Boston, MA 02114, USA
    Ann Clin Psychiatry 19:5-8. 2007
    ..The purpose of this study was to study hopelessness as a predictor of response to fluoxetine in outpatients with Major Depressive Disorder (MDD)...
  41. ncbi Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Psychiatr Res 42:134-40. 2008
    ..09, p=0.569), or HAM-A scores at endpoint (3.30+/-2.89 vs. 3.31+/-2.89, p=0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD...
  42. ncbi A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report
    Andrew A Nierenberg
    Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
    Am J Psychiatry 163:1519-30; quiz 1665. 2006
    ..This study compared the effectiveness of lithium versus triiodothyronine (T(3)) augmentation as a third-step treatment for patients with major depressive disorder...
  43. ncbi Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine
    John W Denninger
    Massachusetts General Hospital, Depression Clinical and Research Program, Dept of Psychiatry, 50 Staniford St, Suite 401, Boston, MA 02114 2541, USA
    Psychosomatics 47:348-52. 2006
    ..Taken together, these findings suggest that developing treatment strategies that successfully target somatic symptoms of depression may further improve the ability to treat depression to remission...
  44. ncbi A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Bulfinch 351, 55 Fruit St, Boston, MA 02114, USA
    Am J Psychiatry 163:1161-72. 2006
    ....
  45. ncbi Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study
    Andrew A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 01224, USA
    J Affect Disord 108:129-34. 2008
    ..It is unknown, however, whether patients with a family member who committed suicide differ from those without such a history...
  46. ncbi Improving depression outcome: new concepts, strategies and technologies
    Jonathan E Alpert
    J Psychopharmacol 20:3-4. 2006
  47. ncbi A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder
    George I Papakostas
    J Clin Psychopharmacol 26:216-8. 2006
  48. ncbi Remissions in maternal depression and child psychopathology: a STAR*D-child report
    Myrna M Weissman
    Department of Psychiatry, Columbia University and the New York State Psychiatric Institute, New York 10032, USA
    JAMA 295:1389-98. 2006
    ..Children of depressed parents have high rates of anxiety, disruptive, and depressive disorders that begin early, often continue into adulthood, and are impairing...
  49. ncbi Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1326-30. 2005
    ..The purpose of this study was to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI)...
  50. ncbi S-adenosyl-methionine in depression: a comprehensive review of the literature
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Curr Psychiatry Rep 5:460-6. 2003
    ..Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system...
  51. ncbi Early-onset depression and the emotional and behavioral characteristics of offspring
    Timothy J Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Depress Anxiety 18:104-8. 2003
    ..This finding may be significant in uncovering sources of vulnerability and formulating intervention strategies for offspring of depressed parents...
  52. ncbi A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 156 Parkman Street, WACC 812, Boston, MA 02114, USA
    Int Clin Psychopharmacol 18:293-6. 2003
    ....
  53. ncbi Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, WACC 812, 15 Parkman Street, Boston, Massachusetts, 02114, USA
    J Nerv Ment Dis 191:444-9. 2003
    ..Furthermore, a full 6-week trial of NT, a relatively noradrenergic tricyclic antidepressant, may be particularly useful in patients who have failed to respond to several antidepressants and also report significant hopelessness...
  54. ncbi Axis III disorders in treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Psychiatry Res 118:183-8. 2003
    ..Thus, the present results cannot be generalized to such populations...
  55. ncbi Serum cholesterol and serotonergic function in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Psychiatry Res 118:137-45. 2003
    ....
  56. ncbi Serum cholesterol in treatment-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Neuropsychobiology 47:146-51. 2003
    ....
  57. ncbi Somatic symptoms in treatment-resistant depression
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 118:39-45. 2003
    ..The overwhelming majority of patients with TRD presented with somatic symptoms. In addition, a greater number of somatic symptoms during the screen visit placed patients at risk for further treatment resistance...
  58. ncbi Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks
    Jonathan E Alpert
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychother Psychosom 72:102-6. 2003
    ..This finding may be important in identifying and formulating intervention strategies for childhood problems in the offspring of depressed parents...
  59. ncbi Nortriptyline for treatment-resistant depression
    Andrew A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, USA
    J Clin Psychiatry 64:35-9. 2003
    ..This study assesses the efficacy of nortriptyline for patients with treatment-resistant major depression...
  60. ncbi Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants
    Andrew A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 23:92-5. 2003
    ..More definitive data await the outcome of the NIMH Sequential Treatment Alternatives to Relieve Depression (STAR*D) study...
  61. ncbi Functioning and interpersonal relationships as predictors of response in treatment-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Compr Psychiatry 44:44-50. 2003
    ..Beyond a history of nonresponse to antidepressants, long-term occupational function may be a predictor of outcome in the treatment of TRD...
  62. ncbi Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder
    Roy H Perlis
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, 02114, USA
    J Clin Psychopharmacol 22:474-80. 2002
    ....
  63. ncbi Body dysmorphic disorder in outpatients with major depression
    Andrew A Nierenberg
    Depression Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital and The Consolidated Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA
    J Affect Disord 69:141-8. 2002
    ..The purpose of this study was to evaluate the rate of BDD in a cohort of consecutive outpatients with typical and atypical major depressive disorder...
  64. ncbi A survey of prescribing practices in the treatment of depression
    Timothy Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:177-87. 2002
    ..The purpose of this study was to examine prescribing practices in a sample of psychiatrists attending a psychopharmacology review course and compare these results with empirical evidence...
  65. ncbi The impact of medical comorbidity on acute treatment in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Am J Psychiatry 160:2122-7. 2003
    ..The authors investigated the impact of medical comorbidity on the acute phase of antidepressant treatment in subjects with major depressive disorder...
  66. ncbi Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    J Clin Psychiatry 64:1357-61. 2003
    ..The purpose of this study was to test whether the presence of comorbid Axis I and Axis II disorders predicts clinical response to an open trial of nor-triptyline among patients with treatment-resistant depression...
  67. ncbi Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy
    Andrew A Nierenberg
    Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 64:13-7. 2003
    ..In addition, psychotherapy, alone or combined with medication, has been shown to be effective in preventing further episodes of depression...
  68. ncbi Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Psychosom Med 67:703-6. 2005
    ..In this study, we measured the impact of cardiovascular risk factors on the outcome of antidepressant treatment in major depressive disorder (MDD)...
  69. ncbi An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 66:1038-42. 2005
    ..In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment...
  70. ncbi The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:523-8. 2005
    ..05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk...
  71. ncbi The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients
    Amy Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, MA WAC 812, USA
    Int Clin Psychopharmacol 20:87-91. 2005
    ..In conclusion, the presence of early improvement on the HAMD-17 item concerning fatigue and general somatic symptoms is significantly predictive of achieving remission at endpoint with active study treatment but not with placebo...
  72. ncbi Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychol Med 34:1299-308. 2004
    ..Anxious depression, defined as Major Depressive Disorder (MDD) with high levels of anxiety symptoms, may represent a relatively common depressive subtype, with distinctive features...
  73. ncbi Obesity among outpatients with major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:59-63. 2005
    ..Greater relative body weight, but not obesity, predicted non-response. In conclusion, greater relative body weight was found to place MDD outpatients at risk for fluoxetine resistance...
  74. ncbi Psychosocial functioning during the treatment of major depressive disorder with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:507-11. 2004
    ..Therefore, studying the impact of treatment on psychosocial functioning in MDD could help further improve the standard of care...
  75. ncbi Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Psychosomatics 45:419-25. 2004
    ..Greater medical comorbidity was also associated with higher increases in self-reported symptoms of depression, anxiety, and anger during the follow-up...
  76. ncbi Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1096-8. 2004
    ....
  77. ncbi Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1090-5. 2004
    ....
  78. ncbi Psychosocial functioning in patients with treatment resistant depression
    Timothy Petersen
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WAC 812 Boston, MA 02114, USA
    Eur Psychiatry 19:196-201. 2004
    ..This is particularly true for those with treatment resistant depression (TRD). However, to date, no systematic assessments of psychosocial functioning for patients with TRD have been conducted...
  79. ncbi Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Psychiatry Res 126:287-90. 2004
    ..Pre-treatment anxiety was not related to the development of side effects...
  80. ncbi Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02214, USA
    J Clin Psychiatry 65:543-6. 2004
    ..In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)...
  81. ncbi Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    J Clin Psychiatry 65:217-21. 2004
    ..The purpose of this study is to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI)...
  82. ncbi Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 15:187-92. 2003
    ..These findings failed to reveal any relationship between side effects and treatment outcome for patients with MDD enrolled in an 8-week, 20 mg, fixed dose, open trial of fluoxetine...
  83. ncbi NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients
    Timothy Petersen
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, MA, Boston 02114, USA
    Psychiatry Res 109:9-16. 2002
    ....

Research Grants3

  1. RESPONSE VARIABILITY IN TREATMENT RESISTANT DEPRESSION
    Jonathan Alpert; Fiscal Year: 2006
    ..Secondary analyses will use general linear models and growth mixture modeling to examine how early cordance changes relate to patient and illness factors and to functional outcomes. ..